Daily Tech: AI and Automation Themes Accelerate, Latest in Biotech

FutureGate | April 14 2025

Richtech Robotics Advances on Bullish Note from H.C. Wainwright

Shares of Richtech Robotics gained this week following a favorable research note from H.C. Wainwright, which highlighted significant upside potential in the company's robotics-as-a-service business model. Analysts pointed to the company's expanding commercial footprint and high-margin recurring revenue model as catalysts for sustained re-rating. With growing labor shortages and increasing cost sensitivity across industries like hospitality and logistics, demand for scalable automation solutions remains robust. Wainwright's outlook reinforced long-term conviction in service robotics as a secular growth theme.

DoorDash Enters Sidewalk Delivery Race, Rivals Uber-Serve Model

In a strategic move to expand last-mile logistics capabilities, DoorDash announced the deployment of sidewalk delivery robots across key urban markets. This expansion places the company in direct competition with Uber’s Serve Robotics, signaling a deepening investment in autonomous delivery infrastructure. The initiative is aimed at improving cost efficiency and speed of delivery, while also reducing carbon emissions. Analysts see this as a long-term lever for margin enhancement, particularly in high-density areas where human delivery incurs higher costs. The broader autonomous delivery ecosystem continues to attract capital as consumer expectations for speed and convenience escalate.

Solriamfetol Shows 45% Reduction in ADHD Symptoms With Lower Side Effects

In biotech, Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, has shown compelling results in a new clinical study targeting adult ADHD. The trial demonstrated a 45% reduction in core symptoms, with a safety profile that suggests fewer side effects relative to traditional stimulants. This positions Solriamfetol as a potential best-in-class option for a large and under-addressed segment of adult ADHD patients who are non-responsive or intolerant to existing treatments. Analysts expect strong market uptake if approved, particularly in light of growing adult diagnosis rates and increased scrutiny over stimulant-based therapies.

AI Drug Discovery Firms Rally as FDA Backs Modernized Testing Framework

Shares of AI-focused drug discovery companies rallied after the U.S. Food and Drug Administration (FDA) confirmed a phased withdrawal of mandatory animal testing for new drug development. The policy shift opens the door to computational and AI-based preclinical models, significantly reducing time-to-market and R&D costs. Key beneficiaries include platforms using generative AI to simulate molecular behavior, predict efficacy, and screen drug candidates. The change not only supports ethical reform but also marks a major step forward in regulatory modernization, boosting investor confidence in AI-led biopharma innovation. This could catalyze broader capital flows into the digital health and biotech space over the medium term.